News Center

MedScape | June 01, 2020 A blood test detected 11 of 11 cases of colorectal cancer in a study involving 354 patients, and also spotted a majority of cases — 40 out of 53 — in which participants had ad...

Data now available, via 2020 ASCO Virtual Scientific Program, demonstrates early detection of colorectal neoplasia and significant association with size and number of polyps...

OncLive | May 08, 2020 The multimodal FirstSightCRC blood test demonstrated higher sensitivity and specificity than standard screening protocols in detecting advanced adenomas and colorectal cancer (C...

NEW YORK (GenomeWeb) – Researchers shared new data this week from a study of the colorectal cancer screening test being developed by CellMax life, providing the first prospective sensitivity and speci...

MedPage Today | May 7, 2020 Testing blood for three distinct colorectal cancer (CRC) markers showed perfect sensitivity and 90% specificity for detecting malignancy in a preliminary study, researchers...

Healio Gastroenterology | May 6, 2020 A novel, blood-based assay improved the detection of advanced and non-advanced adenomas by analyzing cell-free DNA and circulating gastrointestinal epithelial cel...

Becker’s Hospital Review | May 04, 2020 CellMax Life released results from its U.S. study of the FirstSight blood test that revealed the test detected colorectal cancer with 100 percent sensitiv...

FirstSight test achieved 90% specificity, with sensitivity of 100% and 76% for detection of colorectal cancer and advanced adenomas, respectively. Data is now available via Digestive Disease Week® (DD...

BIOCENTURY | JAN 18, 2018 CellMax Life Inc. (Sunnyvale, Calif.) reported that its CellMax-CRC colorectal cancer screening test detected colorectal cancer with 84% sensitivity and 97.3% specificity. Th...

HealthNewsDigest | Jan 20, 2019 According to the American Society for Gastrointestinal Endoscopy, colorectal cancer (aka colon cancer) is the second leading cause of cancer-related deaths in the Unite...

MD+DI | 01/09/2019 – CellMax Life has developed a blood test that it says can identify precancerous adenomas with similar accuracy as colonoscopy, which may facilitate better compliance with scr...

NEW YORK (GenomeWeb) – JAN 02, 2019 Sunnyvale, California-based CellMax Life said today that it has partnered with Taiwan-based Medigen Biotech as part of the firm’s cell therapy clinical trials. Medi...

CellMax Life said today its CMx™ circulating tumor cell (CTC) platform and liquid biopsy panel will be used by Medigen Biotech in upcoming clinical trials of its cell therapy candidates for cancers, w...

Patents cover entirety of sub-$200 test and platform, which isolates rare circulating tumor cells (CTCs) from one tube of blood CellMax Life, enabling early cancer detection and management with afford...

Chicago Tribune | June 27, 2018 — Medical tests save lives. Discovering diseases before they become more serious can mean the difference between life and death. But many Americans say they don’t have ...

Scientific American | June 20, 2018 — Colorectal Cancer Is on the Rise in Young Adults They’re reluctant to have invasive colonoscopies, but a simple blood test could improve compliance By Shai ...

MedTech Breakthrough Awards, 2018 — Leading Cancer Management Company Wins Prestigious Award for its Proprietary Circulating Tumor Cell (CTC) CMx Platform CellMax Life, a leading cancer detection and ...

Becker’s GI & Endoscopy | May 30, 2018  Cancer diagnostics company CellMaxLife launched Zenith, the U.S. trial of its circulating tumor cell blood test to detect colorectal cancer. Here are ...

ASCO Reading Room 05.31.2018 — A new blood test appears to detect expression of the programmed death-ligand 1 (PD-L1) protein in circulating tumor cells (CTCs) with high sensitivity, enabling repeat t...

NEW YORK (360Dx) – CellMax Life announced this week that it is beginning a new clinical trial, which will further validate its circulating tumor cell (CTC) colorectal cancer screening test in American...